Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 5/20 | 0.62 |
| ▸ | NPFFR2 | Q9Y5X5 | 5/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.62 |
| ▸ | FAAH | O00519 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11455282 | 0.99 | NPFFR1 (0.61) | NPFFR1NPFFR2OPRK1OPRM1OPRD1 | |
| SCHEMBL6045494 | 0.99 | NPFFR1 (0.61) | NPFFR1NPFFR2OPRK1OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL5240984 | 0.99 | NPFFR1 (0.61) | NPFFR1NPFFR2OPRK1OPRM1OPRD1 | |
| SCHEMBL11567112 | 0.91 | FAAH (0.55) | NPFFR1NPFFR2OPRK1OPRM1OPRD1 | |
| SCHEMBL11566176 | 0.91 | FAAH (0.55) | NPFFR1NPFFR2OPRK1OPRM1OPRD1 | |
| SCHEMBL2996293 | 0.89 | CYP2D6 (0.68) | NPFFR1NPFFR2OPRK1OPRM1OPRD1 | |
| SCHEMBL3169662 | 0.87 | NPFFR1 (0.58) | NPFFR1NPFFR2OPRK1OPRM1OPRD1 | |
| SCHEMBL11568366 | 0.87 | CYP2D6 (0.58) | NPFFR1NPFFR2OPRK1OPRM1OPRD1 | |
| SCHEMBL7830278 | 0.87 | ALDH1A1 (0.63) | NPFFR1NPFFR2OPRK1OPRM1OPRD1 | |
| SCHEMBL3171094 | 0.86 | NPFFR1 (0.60) | NPFFR1NPFFR2OPRK1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102442937-B | Method for preparing 1-benzyl-4-aniline piperidine-4-carboxylic acid | SICHUAN SAINANDE TECHNOLOGY CO LTD | 2013-11-13 | — | — | CN | claimed |
| CN-102442937-A | Method for preparing 1-benzyl-4-anilinopiperidine-4-carboxylic acid | SICHUAN SAINANDE TECHNOLOGY CO LTD | 2012-05-09 | — | — | CN | claimed |
| EP-0433048-A1 | Preparation of substituted alkali metal piperidine-4-carboxylates | GLAXO WELLCOME INC. (US) | 1991-06-19 | — | — | EP | claimed |
| JP-7165713-A | — | — | None | — | — | JP | disclosed |
| WO-2022267798-A1 | μ/δ OPIOID RECEPTOR DUAL AGONIST AND MEDICAL USE THEREOF | 中国人民解放军军事科学院军事医学研究院 | 2022-12-29 | — | — | WO | disclosed |
| WO-2022267798-A1 | μ/δ OPIOID RECEPTOR DUAL AGONIST AND MEDICAL USE THEREOF | 中国人民解放军军事科学院军事医学研究院 | 2022-12-29 | — | — | WO | disclosed |
| EP-3643704-B1 | NEW INTERMEDIATES FOR THE PREPARATION OF REMIFENTANIL HYDROCHLORIDE | HAMELN PHARMA GMBH (DE) | 2020-12-16 | — | — | EP | disclosed |
| US-10844014-B2 | Intermediates for the preparation of remifentanil hydrochloride | HAMELN PHARMA GMBH (DE) | 2020-11-24 | — | — | US | disclosed |
| US-20200131127-A1 | INTERMEDIATES FOR THE PREPARATION OF REMIFENTANIL HYDROCHLORIDE | HAMELN PHARMA PLUS GMBH (DE) | 2020-04-30 | — | — | US | disclosed |
| EP-3643704-A1 | NEW INTERMEDIATES FOR THE PREPARATION OF REMIFENTANIL HYDROCHLORIDE | hameln pharma plus gmbh (DE) | 2020-04-29 | — | — | EP | disclosed |
| EP-3199523-A1 | THE NEW PROCESS FOR PRODUCING N-PHENYL-N-(4-PIPERIDINYL) AMIDE DERIVATIVES SUCH AS REMIFENTANIL AND CARFENTANIL | Bioka s. r.o. (SK) | 2017-08-02 | — | — | EP | disclosed |
| US-7208604-B2 | Methods for the synthesis of alfentanil, sufentanil, and remifentanil | MALLINCKRODT INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070054911-A1 | Muscarinic modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2007-03-08 | — | — | US | disclosed |
| US-20070054911-A1 | Muscarinic modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2007-03-08 | — | — | US | disclosed |
| US-20070054911-A1 | Muscarinic modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2007-03-08 | — | — | US | disclosed |
| US-20060252797-A1 | Receptor regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-09 | — | — | US | disclosed |
| WO-2006105035-A2 | MUSCARINIC MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-10-05 | — | — | WO | disclosed |
| EP-1559428-A1 | RECEPTOR REGULATOR | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
| JP-H07165713-A | CHEMICAL PROCESS | GLAXO GROUP LTD | 1995-06-27 | — | — | JP | disclosed |
| EP-0433048-A1 | Preparation of substituted alkali metal piperidine-4-carboxylates | GLAXO WELLCOME INC. (US) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054911-A1 | Muscarinic modulators | CHRM3, CHRM5, CHRM4 | NPFFR1 591/4885NPFFR2 571/4885OPRK1 118/4885 |
| US-20060252797-A1 | Receptor regulator | NMUR1, NMUR2, NMBR | NPFFR1 39/4885NPFFR2 80/4885OPRK1 146/4885 |
| US-10844014-B2 | Intermediates for the preparation of remifentanil hydrochloride | OPRK1, OPRM1, OPRD1 | NPFFR1 1217/4885NPFFR2 969/4885OPRK1 1/4885 |
| US-20200131127-A1 | INTERMEDIATES FOR THE PREPARATION OF REMIFENTANIL HYDROCHLORIDE | OPRK1, OPRM1, OPRD1 | NPFFR1 1217/4885NPFFR2 969/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.